Paranasal Sinus Neoplasms clinical trials
The registry lists 24 studies for Paranasal Sinus Neoplasms across more than 10 countries. 6 are recruiting or about to start. 7 of them are mainly about Paranasal Sinus Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12.
Get an email when these change. Save the Paranasal Sinus Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Johnny Kao (2) · National Cancer Institute (NCI) (2) · Memorial Sloan Kettering Cancer Center (2) · Travera Inc (1) · St. Paul's Sinus Centre (1) · Eye & ENT Hospital of Fudan University (1) · Sun Yat-sen University (1) · Assiut University (1)
What is being tested here
Drugs under test in Paranasal Sinus Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Cisplatin | 1 | 1 | 5 |
| SX-682 | 1 | 0 | 1 |
| Toripalimab | 1 | 0 | 1 |
| Fluorouracil | 0 | 0 | 2 |
| Celecoxib | 0 | 0 | 2 |
| Ipilimumab | 0 | 0 | 1 |
| Nivolumab | 0 | 0 | 1 |
| Etoposide | 0 | 0 | 1 |
| Cetuximab | 0 | 0 | 1 |
| Hydroxyurea | 0 | 0 | 1 |
Drug classes tested here Immune checkpoint inhibitors 1 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 2
- Jun 2027Induction Treatment in SCC of the Head and Neck Region - Concomitant Chemotherapy and Low-dose Radiotherapy · Maria Sklodowska-Curie National Research Institute of Oncology
- Oct 2027Evaluation of Endoscopic Management of Sinonasal Tumors In Difficult Anatomical Locations · Assiut University
Who these studies take
Of the 5 Paranasal Sinus Neoplasms studies recruiting now, 3 (60%) set no upper age limit and 0 (0%) stop at 75 or younger. 1 (20%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (20%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (20%) | 1 (20%) |
| 18 | 4 (80%) | 4 (80%) |
| 30 | 5 (100%) | 5 (100%) |
| 40 | 5 (100%) | 5 (100%) |
| 50 | 5 (100%) | 5 (100%) |
| 65 | 5 (100%) | 5 (100%) |
| 75 | 5 (100%) | 5 (100%) |
| 85 | 5 (100%) | 5 (100%) |
Across all 24 studies, recruiting or not: 4% stop at 75 or younger and 4% at 65; 17% take children; 0% are for women only and 0% for men only; 8% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
What changed recently
From the registry's own updates since Oct 14, 2026.
Started recruiting1
Studies
Recruiting first, then most recently updated. Showing 24 of 24. search them.
- Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate CancerRecruitingNCT07667400Phase 1/21 country
- Toripalimab With Chemotherapy for Sinus CancerRecruitingNCT06940180Phase 21 country
- Integrated Cancer Repository for Cancer ResearchRecruitingNCT020126991 country
- Evaluation of Endoscopic Management of Sinonasal Tumors In Difficult Anatomical LocationsNot yet recruitingNCT07512466Not applicable
- The Head and Neck Registry of the European Reference Network on Rare Adult Solid CancersRecruitingNCT054833743 countries
- Endoscopic Surgery in the Treatment of Soft Tissue Sarcoma in Nasal and Paranasal SinusRecruitingNCT056143751 country
- Induction Treatment in SCC of the Head and Neck Region - Concomitant Chemotherapy and Low-dose RadiotherapyActive, not recruitingNCT05992610Not applicable1 country
- Docetaxel, Cisplatin and Fluorouracil in Treating Patients With Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus CancerTerminatedNCT00707473Phase 21 country
- Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT StudyActive, not recruitingNCT05075980Phase 21 country
- Nivolumab and Ipilimumab in Treating Patients With Rare TumorsActive, not recruitingNCT02834013Phase 22 countries
- Exercise Training and Behavioral Modification for the Improvement of Physical Activity in Head and Neck Cancer Patients Undergoing Cancer TreatmentCompletedNCT04788264Not applicable1 country
- A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal PassagesCompletedNCT03274414Phase 21 country
- Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck CancerTerminatedNCT04162873Phase 21 country
- Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to DrugsWithdrawnNCT04985357
- Utility of Indocyanine Green Fluorescence in Endoscopic Sinonasal and Skull Base SurgeryStatus unknownNCT04374448Not applicable
- Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal SinusesStatus unknownNCT05114707Phase 21 country
- Adaptive Radiotherapy for Head and Neck CancerCompletedNCT03096808Phase 21 country
- Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer.CompletedNCT01469429Phase 1/21 country
- Olfactory Training in Improving Sense of Smell After Radiation Therapy in Patients With Paranasal Sinus or Nasopharyngeal CancerTerminatedNCT03049358Not applicable1 country
- Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)CompletedNCT00117572Phase 35 countries
- Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck CancerCompletedNCT00462735Phase 21 country
- Antineoplaston Therapy in Treating Patients With Advanced Head and Neck CancerTerminatedNCT00003489Phase 21 country
- Erlotinib, Celecoxib and Reirradiation for Recurrent Head and Neck CancerCompletedNCT00970502Phase 1/21 country
- Chemoradiotherapy Followed by Surgery for Advanced Paranasal Sinus CancerWithdrawnNCT00347256Not applicable